Pneumonia burden in severe asthma and COPD with and without inhaled corticosteroid exposure: a real-world comparative cohort study

Background Inhaled corticosteroids (ICS) are central to asthma management and recommended for selected patients with chronic obstructive pulmonary disease (COPD). Comparing pneumonia burden across treatment groups may inform their clinical use. Objective To compare pneumonia burden among patients with severe asthma receiving ICS plus biologic therapy, COPD receiving ICS, and COPD without ICS, and to evaluate the association between ICS exposure and pneumonia within COPD. Methods This single-center retrospective comparative cohort study included 158 adults (50 severe asthma receiving ICS and biologics, 58 COPD receiving ICS, and 50 COPD without ICS) from January 2023–December 2025. Pneumonia was defined using clinical and imaging criteria. COPD-only logistic regression adjusted for age group, sex, and pack-years; exploratory models additionally incorporated BMI, eosinophil count, or individual spirometric indices. Results Pneumonia occurred in 34/158 patients (21.5%): 1/50 (2.0%) with severe asthma, 28/58 (48.3%) with ICS-treated COPD, and 5/50 (10.0%) with COPD without ICS ( p < 0.001). Fifty-eight episodes were recorded, including 52 in ICS-treated COPD. The crude COPD-only OR was 8.40 (95% CI 2.92–24.19). In 95 complete cases (30 pneumonia events), the adjusted OR was 10.06 (95% CI 2.99–33.80); with additional BMI adjustment it was 10.38 (2.97–36.20), with eosinophil adjustment 11.32 (3.19–40.20), and with both 11.93 (3.21–44.36). Conclusions ICS-treated COPD patients had a substantially greater pneumonia burden than those managed without ICS. The association persisted after adjustment for available demographic, smoking, and lung function variables, supporting attention to pneumonia burden during individualized ICS treatment review. The severe asthma comparison was descriptive; residual confounding and wide confidence intervals warrant cautious interpretation of the association.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.1957185
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pneumonia burden in severe asthma and COPD with and without inhaled corticosteroid exposure: a real-world comparative cohort study

Saltuk Buğra Kaya, Yunus Emre Er, Betül Inal, Dilara Sevval Saglik et al.
1 links
Frontiers in Medicine
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Pneumonia burden in severe asthma and COPD with and without inhaled corticosteroid exposure: a real-world comparative cohort study

Saltuk Buğra Kaya, Yunus Emre Er, Betül Inal, Dilara Sevval Saglik, Ipek Balikçi Çiçek
article en

Abstract

Background Inhaled corticosteroids (ICS) are central to asthma management and recommended for selected patients with chronic obstructive pulmonary disease (COPD). Comparing pneumonia burden across treatment groups may inform their clinical use. Objective To compare pneumonia burden among patients with severe asthma receiving ICS plus biologic therapy, COPD receiving ICS, and COPD without ICS, and to evaluate the association between ICS exposure and pneumonia within COPD. Methods This single-center retrospective comparative cohort study included 158 adults (50 severe asthma receiving ICS and biologics, 58 COPD receiving ICS, and 50 COPD without ICS) from January 2023–December 2025. Pneumonia was defined using clinical and imaging criteria. COPD-only logistic regression adjusted for age group, sex, and pack-years; exploratory models additionally incorporated BMI, eosinophil count, or individual spirometric indices. Results Pneumonia occurred in 34/158 patients (21.5%): 1/50 (2.0%) with severe asthma, 28/58 (48.3%) with ICS-treated COPD, and 5/50 (10.0%) with COPD without ICS ( p < 0.001). Fifty-eight episodes were recorded, including 52 in ICS-treated COPD. The crude COPD-only OR was 8.40 (95% CI 2.92–24.19). In 95 complete cases (30 pneumonia events), the adjusted OR was 10.06 (95% CI 2.99–33.80); with additional BMI adjustment it was 10.38 (2.97–36.20), with eosinophil adjustment 11.32 (3.19–40.20), and with both 11.93 (3.21–44.36). Conclusions ICS-treated COPD patients had a substantially greater pneumonia burden than those managed without ICS. The association persisted after adjustment for available demographic, smoking, and lung function variables, supporting attention to pneumonia burden during individualized ICS treatment review. The severe asthma comparison was descriptive; residual confounding and wide confidence intervals warrant cautious interpretation of the association.

Frontiers in MedicineVol. 13
Inonu University (TR)
Good health and well-being
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon